LNS8801

LNS8801 is an investigational agent whose form is not stated in the registry developed by Linnaeus Therapeutics. Its target is Estrogen receptor (ERα). ClinicalTrials.gov describes the intervention as: G protein-coupled estrogen receptor (GPER) agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06624644 (A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma), in melanoma. The largest, NCT06624644, plans to enrol 135 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.